⚡Relatlimab plus nivolumab improved 5-year survival compared to nivolumab alone in patients with advanced melanoma, according to the phase 3 RELATIVITY-047 trial.

"Relatlimab plus nivolumab shows 5-year survival benefit in advanced melanoma" — Nature Medicine · Science & Medicine

24 Oct 2026

What it means

This is a new publication in Nature Medicine reporting the 5-year overall survival data from the trial, which tested the combination of (an anti-LAG-3 antibody) plus (an anti-PD-1 antibody) against nivolumab alone in patients with . The updated results demonstrate a sustained survival advantage for the combination over the monotherapy at five years of follow-up.

Accuracy & sourcesSourced

The claim comes directly from the original peer-reviewed paper published in Nature Medicine, the primary source for the RELATIVITY-047 data. As the definitive study report, it is authoritative for its own findings, though the exact hazard ratios and statistical significance are not specified in the headline.

⚡Relatlimab plus nivolumab improved 5-year survival compared to nivolumab alone in patients with advanced melanoma, according to the phase 3 RELATIVITY-047 trial.

What it means

Accuracy & sourcesSourced

How new

Go deeper